Actively Recruiting
Choice of Anticoagulant for Primary Hemostasis Studies With PFA2004 (Platelet Function Analyser)
Led by Centre Hospitalier Universitaire Dijon · Updated on 2025-09-29
100
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are exploring how different anticoagulants affect the platelet function analysis (PFA) test, which is used to study primary hemostasis and platelet interactions with von Willebrand factor. The study focuses on comparing results from the standard citrate anticoagulant with a new anticoagulant called BAPA, which may have less impact on blood platelets. This observational study is led by Centre Hospitalier Universitaire Dijon and includes patients needing a PFA test for diagnosing von Willebrand disease. Participants will have three additional BAPA tubes of blood collected at the same time as their routine PFA test sample. The BAPA anticoagulant works differently from citrate by blocking coagulation through another mechanism, and the study aims to compare the occlusion time measurements from both anticoagulants. No experimental treatments are given, as this study observes samples collected alongside regular clinical care. During the study, researchers will measure the occlusion time at baseline to assess platelet function. Participation involves providing blood samples during a scheduled hemostasis consultation. The study does not include any changes to usual care or treatments and does not involve long-term follow-up. The total participation time corresponds to the routine consultation and blood sampling visit.
CONDITIONS
Brief Title
Choice of Anticoagulant for Primary Hemostasis Studies With PFA200® (Platelet Function Analyser)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Person having given their non-opposition
- Person of legal age
- Person receiving a haemostasis consultation at the haemophilia and haemorrhagic diseases treatment center followed by a blood sample with a PFA test prescribed by the doctor (the test is not added for the study).
You will not qualify if you...
- Persons under legal protection (curatorship, guardianship)
- Persons subject to a court protection order
- Pregnant, parturient or breast-feeding women
- Adult incapable or unable to give consent
- Minor
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Day of PFA test
Participants undergo a routine PFA test for the diagnosis of Willebrand disease, during which additional blood samples are collected.
1 visit (in-person)
Duration - Up to study completion in December 2025
Participants are observed following the diagnostic evaluation to collect data on occlusion time measurement.
No additional visits; data collected from routine care
Trial Site Locations
Total: 1 location
1
CHU Dijon Bourgogne
Dijon, France, 21000
Actively Recruiting
Research Team
E
Emmanuel De Maistre
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here